Cineverse Corp. Key Metrics

2 years of history · ending 2025-03-31 · SEC EDGAR

Forensics

Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.

F-Score (Piotroski 0-9)

Z-Score (Altman; <1.81 = distress)

Per Share Metrics

Turnover & Efficiency Analysis (days)

Expense Ratios

Working Capital Analysis

Valuation Multiples

Cash-Flow Multiples

Enterprise Value Multiples

52-Week Range

Trailing Returns

ROIC vs WACC

Yields

Capital Deployment Yields

Liquidity & Leverage Ratios

Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)

EPS (Diluted)
$0
Book Value Per Share
$2
Free Cash Flow Per Share
$1
Cash Per Share
$1
Revenue Per Share
$4
OCF Per Share
$1
Return on Equity
10.6%
Return on Assets
5.5%
Return on Invested Capital
21.7%
Debt to Equity
Current Ratio
1.11
Quick Ratio
1.11
Asset Turnover
1.14
Days Sales Outstanding
73.54
Days Payables Outstanding
Days Inventory On Hand
Cash Conversion Cycle
R&D / Revenue
SBC / Revenue
2.5%
Capex / Revenue
2.2%
Working Capital
$4M
Net Current Asset Value
$3M
Invested Capital
$39M
OCF / Net Income
4.63
FCF / Net Income
4.63
Accruals Ratio (Sloan)
-18.8%
Net Debt
$-14M
Net Debt / EBITDA
-1.19
Interest Coverage
1.82
Cash Coverage
3.99
Capex Coverage
-9.91
Tangible Common Equity
$14M
TCE / Total Assets
19.0%
Goodwill / Total Assets
9.4%
NOPAT
$8M
Cash ROIC
49.1%
WC / Revenue
4.7%
Capex / D&A
0.28
Reinvestment Rate
-47.9%
Total Payout Ratio
5.7%
Asset Growth vs Revenue Growth
-46.5%
Revenue 5Y CAGR
14.8%
FCF 5Y CAGR
17.5%
EBITDA 5Y CAGR
18.4%
Stock Price (FY-end)
$3
Market Cap
$56M
P/E Ratio
14.96
P/S Ratio
0.72
P/B Ratio
1.45
P/TB Ratio
4.08
P/OCF Ratio
3.23
P/FCF Ratio
3.23
Enterprise Value
$42M
EV / EBITDA
3.61
EV / Sales
0.54
EV / FCF
2.43
FCF Yield
30.9%
Shareholder Yield
-3.0%
Buyback Yield
0.4%
Capex Yield
6.3%
Operating Leverage
64.21
Graham Number
$3
Shares Variation (YoY)
45.4%
Beta (5Y)
1.22
Cost of Equity
10.6%
Cost of Debt (after tax)
52W High
$5
52W Low
$1
Trailing Return 1Y
130.7%
Trailing Return 5Y
-47.3%
F-Score (Piotroski)
6.00
Z-Score (Altman)
-7.20

Earnings Forecasts

Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).

Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.

EPS — Consensus vs Actual

Revenue — Consensus vs Actual

Stock Price on Earnings Dates

Cineverse Corp. — Effective Tax Rate ReconciliationNEW

Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.

Effective Rate Trend

Reconciliation LineFY2020FY2021FY2022FY2023FY2024FY2025
Federal Statutory Rate21.00%21.00%21.00%21.00%21.00%21.00%
State & Local Income Taxes-0.10%5.70%-83.70%8.00%8.70%2.60%
Foreign Rate Differential
Other Adjustments0.00%0.10%0.20%-0.10%0.20%
SBC (Nondeductible)-3.40%-3.40%31.50%-8.30%-1.00%5.90%
Valuation Allowance Change-9.90%-26.70%137.00%-27.80%-22.50%-44.30%
Tax Law Change0.00%
Effective Tax Rate-2.20%0.50%-53.20%-1.30%-0.10%2.70%

Cash vs Accrual

ItemFY2020FY2021FY2022FY2023FY2024FY2025
Income Tax Expense (Accrual)$313.0K−$315.0K−$788.0K$119.0K$10.0K$106.0K
Income Taxes Paid (Cash)

Cineverse Corp. — M&A AcquisitionsNEW

Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.

Bloody Disgusting LLC